PP
REGN icon

PDT Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

PDT Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,058
Closed -$4.32M – 837
2024
Q4 		$4.32M Buy
6,058
+3,057
+102% +$2.57M 0.38% 60
2024
Q3 		$3.15M Buy
3,001
+1
+0% +$1.11K 0.28% 105
2024
Q2 		$3.15M Buy
+3,000
New +$2.91M 0.3% 99
2023
Q4 		– Sell
-2,301
Closed -$1.89M – 651
2023
Q3 		$1.89M Buy
+2,301
New +$1.81M 0.24% 139
2022
Q1 		– Sell
-500
Closed -$316K – 1080
2021
Q4 		$316K Buy
+500
New +$307K 0.02% 653
2021
Q2 		– Sell
-502
Closed -$238K – 935
2021
Q1 		$238K Buy
+502
New +$244K 0.02% 665
2020
Q3 		– Sell
-13,304
Closed -$8.3M – 837
2020
Q2 		$8.3M Sell
13,304
-17,096
-56% -$9.7M 0.56% 32
2020
Q1 		$14.8M Buy
30,400
+1,399
+5% +$577K 1.18% 6
2019
Q4 		$10.9M Sell
29,001
-5,404
-16% -$1.82M 0.67% 13
2019
Q3 		$9.54M Buy
34,405
+6,398
+23% +$1.89M 0.57% 46
2019
Q2 		$8.77M Buy
28,007
+3
+0% +$999 0.52% 76
2019
Q1 		$11.5M Sell
28,004
-10
-0% -$4.12K 0.65% 30
2018
Q4 		$10.5M Buy
28,014
+13
+0% +$4.76K 0.58% 40
2018
Q3 		$11.3M Buy
+28,001
New +$10.7M 0.47% 56
2015
Q4 		– Sell
-40,498
Closed -$18.8M – 839
2015
Q3 		$18.8M Buy
+40,498
New +$21.7M 0.42% 48
2015
Q2 		– Sell
-31,740
Closed -$14.3M – 1590
2015
Q1 		$14.3M Buy
+31,740
New +$13.5M 0.36% 48
2014
Q4 		– Sell
-64,420
Closed -$23.2M – 1004
2014
Q3 		$23.2M Sell
64,420
-48,118
-43% -$16.1M 0.59% 28
2014
Q2 		$31.8M Buy
112,538
+45,854
+69% +$13.6M 0.85% 9
2014
Q1 		$20M Buy
+66,684
New +$20.5M 0.48% 37
2013
Q4 		– Sell
-13,954
Closed -$4.37M – 1060
2013
Q3 		$4.37M Buy
+13,954
New +$3.67M 0.12% 217

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PDT Partners's REGN Position: Q1 2025 in Review

PDT Partners sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 6,058 shares — an estimated $4.32M sold.

PDT Partners first reported a position in REGN in Q3 2013 and held it in 20 quarters. The position peaked at $31.8M in Q2 2014. 1,292 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

  • PDT Partners reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • PDT Partners sold 6,058 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $4.32M.
  • PDT Partners first reported a position in Regeneron Pharmaceuticals in Q3 2013 and held it in 20 quarters.
  • PDT Partners's Regeneron Pharmaceuticals position peaked at $31.8M in Q2 2014.
  • 1,292 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on PDT Partners's 13F filing for Q1 2025, filed 15 May 2025.